Oncology 04/2023 Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma Clinical Cancer Research Graviton Love0
Oncology 02/2023 Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development HCC-TAG Graviton Love0
Oncology 07/2022 Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer Nature Communications Graviton Love0
Oncology 01/2022 Therapeutic efficacy of FASN inhibition in preclinical models of HCC Hepatology Graviton Love9
Oncology 04/2021 First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors EClinicalMedicine Graviton Love9
Oncology 09/2020 TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma European Society for Medical Oncology (ESMO) Congress Graviton Love9
Oncology 06/2019 Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab ASCO Graviton Love8
Oncology 12/2018 FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer San Antonio Breast Cancer Symposium natalia Love10
Oncology 11/2018 Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology natalia Love8
Oncology 10/2017 Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis AASLD Graviton Love6